Απάντώντας σε άλλο φόρουμ σε κάποιον που στη συμπεριφορά μοιάζει με τον MEGA GNOSTI AGGLIKON του phorum
Δεν είπα ότι είναι γεμάτη ηλίθιους. Είναι πολλοί όμως και είναι πολύ χαμηλό το μορφωτικό επίπεδο τους. Μην επεκταθώ στα υπόλοιπα.
Δεν είπα ότι συμβαίνει μόνο στην Ελλάδα. Συμβαίνει παντού, αλλού περισσότερο αλλού λιγότερο.
Προφανώς δεν είπα ότι είμαι "απλοϊκός εξυπνάκιας". Δικός σου προσδιορισμός είναι, γιατί δεν σου άρεσε το κυνικό και όχι ελιτίστικο σχόλιο μου.
Είπα το απλό. Βλέποντας τι υπάρχει γύρω σου, ακόμα και σε forum, καταλαβαίνεις γιατί έχεις πετύχει, όπου έχεις πετύχει.
Το αν περνάω τον πήχη των ψεκασμένων 2 φορές ή 100 φορές δεν το ξέρεις. Σίγουρα όμως τον περνάω εύκολα.
Δεν λέω γιατρουδάκο τον Τσιόδρα και έχω την αντίληψη να ξεχωρίσω δημοσίευση στο "New England Journal of Medicine" από ψεκασμένα blog.
Όχι φίλε, σε όσους έχουν διαφορετική άποψη μας αποκαλείτε ηλίθιους και μας προσάπτετε διάφορα επίθετα όπως 5Gάκηδες, ανεγκέφαλους, αντιεμβολιαστές, αρνητές ιών ( έχετε μεγάλη φαντασία) φτωχαδάκια (έυγε) και ένα σωρό.
Αφού έχεις την αντίληψη να ξεχωρίσεις δημοσίευση στα περιβόητα ιατρικά journals σε σχέση με εμάς τους ψεκασμένους, πάρε κάτι ωραίες δηλώσεις από κάποιους ψεκασμένους συντάκτες των journals. Να με συγχωρήσετε όσοι δεν γνωρίζετε καλά αγγλικά γιατί δεν προλαβαίνω να μεταφράσω παρά μόνο την πρώτη δήλωση, είμαι κουρασμένος και αγχωμένος που θα ανοίξω αύριο το μαγαζί.
.Even the editors of main journals themselves recognise that peer review may not be the best system ever devised by mankind. Here is what Richard Horton, the editor of The Lancet, has to say on the matter:
“The mistake, of course, is to have thought that peer review was any more than a crude means of discovering the acceptability — not the validity — of a new finding. Editors and scientists alike insist on the pivotal importance of peer review. We portray peer review to the public as a quasi-sacred process that helps to make science our most objective truth teller. But we know that the system of peer review is biased, unjust, unaccountable, incomplete, easily fixed, often insulting, usually ignorant, occasionally foolish, and frequently wrong.”
Ακόμα και οι ίδιοι συντάκτες των σημαντικών (ιατρικών) περιοδικών (journals) αναγνωρίζουν ότι η εξέταση από ομότιμους (peer review) πιθανόν δεν είναι το καλύτερο σύστημα που επινοήθηκε ποτέ από την ανθρωπότητα. Παρακάτω είναι τι είπε ο Richard Horton, ο αρχισυντάκτης του Lancet, πάνω στο θέμα:
" Το λάθος φυσικά είναι ότι έχουμε θεωρήσει ότι η εξέταση από ομότιμους ήταν κάτι παραπάνω από μία ωμή μέθοδος στο να διαπιστώνουμε την αποδεκτικότητα - όχι την εγκυρότητα - ενός νέου ευρήματος. Οι συντάκτες όσο και οι επιστήμονες, επιμένουν ότι είναι ζωτικής σημασίας η εξέταση από ομότιμους. Παρουσιάζουμε την εξέταση από ομότιμους στο ευρύ κοινό ως μια "ιερή" μέθοδο που μας βοηθάει να καταστήσουμε την επιστήμη ως τον πιο αμερόληπτο αφηγητή της αλήθειας. Αλλά ξέρουμε ότι το σύστημα της εξέτασης από ομότιμους είναι μεροληπτικό, άδικο, ατελές, εύκολα φτιαχτό, μη υπόλογο, συχνά προσβλητικό, συνήθως αδαές, περιστασιακά ανόητο και πολύ συχνά λάθος."
A view supported from a slightly different angle by Dr Marcia Angell, who was the editor of the New England Journal of Medicine for two decades. This was, and remains, the single most powerful and influential medical journal in the world. At least it is, when it comes to citations and impact factor:
“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.”
As for the quality of published research itself, here is one of my favourite quotes by Drummond Rennie, at the time the Deputy Editor of the Journal of the American Medical Association:
“There seems to be no study too fragmented, no hypothesis too trivial, no literature citation too biased or too egotistical, no design too warped, no methodology too bungled, no presentation of results too inaccurate, too obscure, and too contradictory, no analysis too self serving, no argument too circular, no conclusions too trifling or too unjustified, and no grammar and syntax too offensive for a paper to end up in print.”[78]
from a talk by Richard Smith (ex-editor of the BMJ):[79]
“Examples of Methods for Pharmaceutical Companies to Get the Results They Want from Clinical Trials:
Conduct a trial of your drug against a treatment known to be inferior;
Trial your drugs against too low a dose of a competitor drug;
Conduct a trial of your drug against too high a dose of a competitor drug (making your drug seem less toxic);
Conduct trials that are too small to show differences from competitor drugs;
Use multiple endpoints in the trial and select for publication those that give favourable results;
Do multicentre trials and select for publication, results from centres that are favourable;
Conduct subgroup analyses and select for publication those that are favourable;
Present results that are most likely to impress – for example, reduction in relative rather than absolute risk.
“The British Medical Journal (BMJ) has alleged that pharmaceutical giant Roche is deliberately hiding clinical trial data about the efficacy of oseltamivir (Tamiflu) in patients with influenza. The journal says global stockpiling and routine use of the drug are not supported by solid evidence and alleges that Roche concealed neurological and psychiatric adverse events associated with the neuraminidase inhibitor drug.
“In an open letter from Fiona Godlee, MD, editor-in-chief of BMJ, to Professor John Bell, FRS, HonFREng, PMedSci, Regius Professor of Medicine at Oxford University in the United Kingdom and a Roche board member, published online December 2012, Dr Godlee reminds Bell of concerns that were initially voiced in 2009 about the reliability of Tamiflu research.
“At that time, BMJ published an updated Cochrane review of neuraminidase inhibitors in healthy adults. That study ‘took the view that, since eight of the 10 [randomized controlled trials] on which effectiveness claims were based, were never published, and because the only two that had been published were funded by Roche and authored by Roche employees and Roche-paid external experts, the evidence could not be relied upon,’ Dr Godlee writes.”
“Academics with competing interests were nearly six times as likely as those without industry links (p=0.009) to predict a higher risk to the public from the pandemic than was given by official agencies… Academics who promoted the use of antiviral drugs in the UK media during the 2009-10 HIN1 flu pandemic were eight times as likely to have links with the drug industry as quoted academics who didn’t comment on their use.”
http://jech.bmj.com/content/early/2013/ ... 03128.full
“‘Journals have devolved into information laundering operations for the pharmaceutical industry’, wrote Richard Horton, editor of The Lancet, in March 2004. In the same year, Marcia Angell, former editor of the New England Journal of Medicine, lambasted the industry for becoming ‘primarily a marketing machine’ and co-opting ‘every institution that might stand in its way.’
“Jerry Kassirer, another former editor of the New England Journal of Medicine, argues that the industry has deflected the moral compasses of many physicians, and the editors of PLoS Medicine have declared that they will not become ‘part of the cycle of dependency …between journals and the pharmaceutical industry.’
“Twenty years ago this week the statistician Doug Altman published an editorial in the BMJ arguing that much medical research was of poor quality and misleading. In his editorial entitled, ‘The Scandal of Poor Medical Research,’ Altman wrote that much research was ‘seriously flawed through the use of inappropriate designs, unrepresentative samples, small samples, incorrect methods of analysis, and faulty interpretation.’ Twenty years later I fear that things are not better but worse…
“…’The poor quality of much medical research is widely acknowledged,’ wrote Altman, ‘yet disturbingly the leaders of the medical profession seem only minimally concerned about the problem and make no apparent efforts to find a solution.’
“Altman’s conclusion was: ‘We need less research, better research, and research done for the right reasons. Abandoning using the number of publications as a measure of ability would be a start.’
“Sadly, the BMJ could publish this editorial almost unchanged again this week. Small changes might be that ethics committees are now better equipped to detect scientific weakness and more journals employ statisticians. These quality assurance methods don’t, however, seem to be working as much of what is published continues to be misleading and of low quality. Indeed, we now understand that the problem doesn’t arise from amateurs dabbling in research but rather from career researchers.”
Richard Smith finishes this particular blog…
“I reflect on all this in a very personal way. I wasn’t shocked when we published Altman’s editorial because I’d begun to understand about five years’ before that much research was poor. Like Altman I thought that that was mainly because too much medical research was conducted by amateurs. It took me a while to understand that the reasons were deeper. In January 1994 at age 41, when we published Altman’s editorial, I had confidence that things would improve. In 2002 I spent eight marvellous weeks in a 15th century palazzo in Venice writing a book on medical journals, the major outlets for medical research, and reached the dismal conclusion that things were badly wrong with journals and the research they published. I wondered after the book was published if I’d struck too sour a note, but now I think it could have been sourer. My confidence that ‘things can only get better’ has largely drained away, but I’m not a miserable old man. Rather I’ve come to enjoy observing and cataloguing human imperfections, which is why I read novels and history rather than medical journals.”
υ.γ σεντόνι βγήκε
Επεξ/σία 11 Μαϊου από Unholydiver